Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26MELBOURNE, Australia, May 20,...
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26MELBOURNE, Australia, May 20,...
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment...
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical...
Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains...
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices,...
Oslo, Norway, 20 May 2026 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting...
MORRISVILLE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Ashley McKeon, a seasoned agriculture and sustainability executive, will lead the Soil...
TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“PharmAla” or the “Company”), a...
31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three...
Company to Hold its Fifth Annual ‘Investor Sesh’ in Appreciation of Investor Support and in Commitment to Transparency for ShareholdersLONG...
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial...
Multi-year partnership lands as Prenetics’ IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x...
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative...
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3...
Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB...
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards...
23andMe’s new AI Health Summary Turns Genetics, Medical Records, Labs, and Lifestyle Data Into Personalized, Evidence-Based RecommendationsPALO ALTO, Calif. and...
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise...
New lung cancer and respiratory treatments are being developed faster than critically ill Canadian patients can access them, even when...
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic...